Login / Signup

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study.

Vincenzo CarnovalePaola IacotucciVito TerlizziCarmela ColangeloLorenza FerrilloAngela PepeMichela FrancalanciGiovanni TaccettiSerena BuonaurioAssunta CelardoLaura SalvadoriGiovanni MarsicovetereMichele D'AndriaNicola FerraraDonatello Salvatore
Published in: Journal of clinical medicine (2022)
genotype, ETI was safe and associated with clinical improvement.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • cystic fibrosis
  • chronic kidney disease
  • prognostic factors
  • randomized controlled trial
  • clinical trial
  • patient reported outcomes
  • placebo controlled